Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

Sixty-three natalizumab-treated patients with relapsing multiple sclerosis were screened for JC polyomavirus (JCV) viruria. Urinary-positive patients were longitudinally sampled for up to 24 weeks. Using methods that distinguish encapsidated virus from naked viral DNA, 17.5 % of patients were found...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Milton H., Huang, DeRen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127893/
https://www.ncbi.nlm.nih.gov/pubmed/27198748
http://dx.doi.org/10.1007/s13365-016-0449-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127893/
https://www.ncbi.nlm.nih.gov/pubmed/27198748
http://dx.doi.org/10.1007/s13365-016-0449-0

Ejemplares similares